Status:

TERMINATED

Oscillation and Lung Expansion (OLE) Therapy for Treatment of Neuromuscular Disease (NMD) Patients

Lead Sponsor:

Baxter Healthcare Corporation

Collaborating Sponsors:

Science 37

Conditions:

Neuromuscular Diseases

Eligibility:

All Genders

5-80 years

Phase:

NA

Brief Summary

The study will be a non-randomized open label pilot study comparing a retrospective control period to an active treatment period with oscillation and lung expansion (OLE) therapy.

Detailed Description

The study is a decentralized trial. All data will be collected in the patients' homes. The primary objective of the study is to evaluate the impact of OLE to treat respiratory complications of neuromu...

Eligibility Criteria

Inclusion

  • Patients who met all the following inclusion criteria are included in the study:
  • Documented diagnosis of neuromuscular disease (NMD) or neurological disorder.
  • Age 5 to 80 years.
  • History of one or more respiratory exacerbations in the past 6 months or two or more respiratory exacerbations in the past 12 months, which required unplanned or unscheduled medical intervention.
  • Ability to perform Oscillation and Lung Expansion (OLE) therapy as directed.
  • Signed informed consent (and assent if minor patient).
  • Patients who meet any of the following criteria will be excluded from the study:
  • Diagnosis with rapidly progressing NMD such as certain types of Motor Neuron Disease (MND).
  • Requirement for continuous mechanical ventilation.
  • Anticipated requirement for respiratory related hospitalization within the next six months.
  • History of pneumothorax within the past 6 months.
  • History of hemoptysis requiring embolization within past 12 months.
  • Pregnancy.
  • Home use of OLE therapy within the past 12 months.
  • Inability or unwillingness to perform OLE therapy or study procedures as required.

Exclusion

    Key Trial Info

    Start Date :

    November 4 2021

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    February 27 2024

    Estimated Enrollment :

    41 Patients enrolled

    Trial Details

    Trial ID

    NCT05366010

    Start Date

    November 4 2021

    End Date

    February 27 2024

    Last Update

    July 31 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Science 37

    Durham, North Carolina, United States, 27709